American Heart Journal
Volume 150, Issue 3 , Pages 471-477 , September 2005

Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure

  • Robert L. Fitzgerald, PhD

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • Department of Pathology, University of California San Diego, San Diego, Calif
    • ,
  • Rosemary Cremo, RN

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • ,
  • Nancy Gardetto, NP

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • ,
  • Albert Chiu, BS

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • ,
  • Paul Clopton, MS

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • ,
  • Vikas Bhalla, MD

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • ,
  • Alan S. Maisel, MD, FACC

      Affiliations

    • Veterans Affair, Medical Center, San Diego, Calif
    • Department of Medicine, University of California San Diego, San Diego, Calif
    • Corresponding Author InformationReprint requests: Alan Maisel, MD, FACC, Division of Cardiology, Department of Medicine, University of California San Diego, VAMC-111A, 3350 La Jolla Village, San Diego, CA 92161.

Received 22 June 2004 ,Accepted 13 November 2004.

References 

  1. American Heart Association. Heart disease and stroke statistics—2003 update. Dallas (Tex): American Heart Association; 2002;
  2. O'Connell J, Bristol MR. Economic impact of heart failure in the United States. J Heart Lung Transplant. 1994;13:S107–S112
  3. McCullough PA, Philbin EF, Spertus JA, et al. Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (R.E.A.C.H.) study. J Am Coll Cardiol. 2002;39:60–69
  4. Abraham WT, Lows BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  5. Publication Committee for the VMAC Investigators. Intravenous nesiritide versus nitroglycerin for the treatment of decompensated congestive heart failure—a randomized controlled trial. JAMA. 2002;287:1531–1540
  6. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med. 2002;3:S18–S27
  7. Emerman CL. Safety and Efficacy of nesiritide for the treatment of decompensated heart failure. Rev Cardiovasc Med. 2002;3:S28–S34
  8. Cheng V, Kazanegra R, Garcia A, et al. A rapid bedside test for peptide (BNP) predicts treatment outcomes in patients admitted for decompensated heart failure. J Am Coll Cardiol. 2001;37:386–391
  9. Bettencourt P, Ferreira S, Azevedo A, et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med. 2002;113:215–219
  10. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  11. Kazanegra R, Chen V, Garcia A, et al. A rapid test for B-type natriuretic peptide (BNP) correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21–29
  12. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;19:1735–1743
  13. Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89:879–881
  14. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–832
  15. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253
  16. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem. 2003;49:1560–1562
  17. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280–1287
  18. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther. 1999;289:976–980
  19. Levin ER, Gardner DG, Samson WK. Mechanisms of disease: natriuretic peptides. N Engl J Med. 1998;339:321–328
  20. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail. 2004;6:351–354
  21. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301–308

PII: S0002-8703(04)00875-0

doi: 10.1016/j.ahj.2004.11.021

American Heart Journal
Volume 150, Issue 3 , Pages 471-477 , September 2005

Article Tools

* Image Usage & Resolution